Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (68Ga-PSMA) positron-emission/computed tomography after radical prostatectomy with pathological node-positive extended lymph node dissection by Huits, T.H. (Thijs H.) et al.
Distribution of prostate cancer recurrences on
gallium-68 prostate-specific membrane antigen
(68Ga-PSMA) positron-emission/computed
tomography after radical prostatectomy with
pathological node-positive extended lymph node
dissection
Thijs H. Huits*, Henk B. Luiting† , Henk G.van der Poel* , Rohan Nandurkar‡ ,
Maarten Donswijk§, Eva Schaake–, Wouter Vogel§,–, Monique J. Roobol† , Esther Wit*,
Phillip Stricker**,†† , Louise Emmett‡,†† and Pim J.van Leeuwen*
*Department of Urology, Netherlands Cancer Institute, Amsterdam, †Department of Urology, Erasmus Medical Centre,
Rotterdam, The Netherlands, ‡St Vincent's Hospital Nuclear Medicine and PET Department, Darlinghurst, NSW,
Australia, §Department of Nuclear Medicine, ¶Department of Radiation Oncology, The Netherlands Cancer Institute,
Amsterdam, The Netherlands, **St. Vincent's Prostate Cancer Centre, and ††Garvan Institute of Medical Research,
Darlinghurst, NSW, Australia
T. H. H. and H. B. L. contributed equally to this paper.
Objectives
To examine the anatomical distribution of prostate cancer
(PCa) recurrence on gallium-68 prostate-specific membrane
antigen (68Ga-PSMA) positron-emission tomography
(PET)/computed tomography (CT) in patients with
biochemical recurrence (BCR) after undergoing radical
prostatectomy (RP) with pathological lymph node metastasis
(pN1) in their extended pelvic lymph node dissection
(ePLND), and to compare the location of PCa recurrence
with the location of the initial lymph node metastasis at
ePLND.
Materials and Methods
We retrospectively reviewed 100 patients with BCR (PSA
0.05–5.00 ng/mL) after RP with pN1 ePLND who underwent
68Ga-PSMA PET/CT to guide salvage therapy. Clinical and
pathological features and anatomical locations of PCa
recurrence on 68Ga-PSMA PET/CT were obtained, and
management impact was recorded.
Results
In all, 68 patients (68%) had a positive and 32 patients (32%)
had a negative 68Ga-PSMA PET/CT result. Of the 68 patients
with a positive 68Ga-PSMA PET/CT, 44 (65%) showed
abnormal uptake only in the pelvic area, seven (10%) only
outside the pelvic area, and 17 (25%) both within and outside
the pelvic area. 68Ga-PSMA PET/CT-positive pelvic lymph
nodes were often (84%) detected on the same side as the
lymph node metastasis diagnosed at ePLND. Based on the
outcomes of the 68Ga-PSMA PET/CT, change of management
was noted in 68% of the patients.
Conclusion
Recurrence of PCa on 68Ga-PSMA PET/CT was limited to
the pelvis in the majority of patients with BCR after RP with
pN1 ePLND. Moreover, recurrence was often detected on the
same side as the lymph node metastasis at ePLND. The
results confirm the diagnostic value of 68Ga-PSMA PET/CT
in patients with BCR after RP with pN1 ePLND. Prospective
studies are needed to support the long-term benefit of 68Ga-
PSMA PET/CT-dictated management changes.
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Introduction
In patients with biochemical recurrence (BCR) after radical
prostatectomy (RP) without evidence of lymph node
metastases, salvage radiotherapy to the prostatic fossa is the
most effective treatment option with curative intent [1-4].
However, for patients with BCR after a pathological node-
positive (pN1) extended pelvic lymph node dissection
(ePLND) at the time of RP, salvage radiotherapy to the
prostatic fossa is not the standard of care because of a lack of
consistent evidence [5,6]. According to the guidelines of the
European Association of Urology, three management options
have to be discussed with patients with pN1 ePLND at RP:
either to start androgen deprivation therapy (ADT), adjuvant
ADT combined with radiotherapy, or observation [7].
Improved survival is seen in retrospective analyses of patients
receiving ADT and adjuvant radiotherapy in comparison to
patients receiving ADT or observation only [8]. Although not
mentioned in the guidelines, clinicians frequently recommend
observation with possible salvage radiotherapy to the prostatic
fossa and pelvic lymph nodes in case of BCR in patients with
pN1 at ePLND. This strategy aims to reduce overtreatment
with adjuvant therapies and might avoid unsuccessful
radiotherapy if early prostate cancer (PCa) recurrence is
detected outside the pelvis (M1).
Gallium-68 prostate-specific membrane antigen (68Ga-PSMA)
positron-emission tomography (PET)/CT has been shown to
improve the detection of metastatic disease in PCa,
particularly in the setting of disease recurrence [9,10]. The
objective of this study is to determine the anatomical
distribution of PCa recurrence and to compare this location
with that of the initial lymph node metastasis on ePLND.
Furthermore, we evaluated 68Ga-PSMA PET/CT-induced
management changes in patients considered for salvage
radiotherapy to the prostatic fossa and pelvic lymph nodes.
Materials and Methods
General
This retrospective analysis was conducted after obtaining the
approval of the Netherlands Cancer Institute (RBd19081). At
the Erasmus Medical Centre, all patients have given consent
to be included in the imPRINT prospective database (NL7165
[NTR7389]). At St Vincent’s Hospital, Sydney, all patients
have given consent to be included in the Prostate Cancer
Imaging Database (ProCan-I). The ProCan-I was approved by
the Institutional Human Research and Ethics Committee of St
Vincent’s Hospital, Sydney.
Patient Population
Between February 2015 and January 2019, 68Ga-PSMA PET/
CT was undertaken in 100 patients with BCR (defined as
PSA ≥ 0.05 ng/mL) after RP with one or more lymph node
metastases on ePLND. Patients treated with radiotherapy or
any systematic treatment after RP or who had a PSA level ≥
5.0 ng/mL at the time of 68Ga-PSMA PET/CT were excluded.
Data on the clinical and pathological features and anatomical
locations of PCa recurrence on 68Ga-PSMA PET/CT were
retrospectively collected from the electronic patient files. The
data were gathered from patients treated in the Netherlands
Cancer Institute (Amsterdam, n = 55), the Erasmus Medical
Centre (Rotterdam, n = 28), and St Vincent’s Prostate Cancer
Centre (Sydney, n = 17).
Imaging Protocol
68Ga-PSMA-11 was used as the tracer and produced on-site
according to the Good Manufacturing Practices regulations.
The tracer was administered to the patients as an i.v. bolus
injection (2.0 MBq/kg, St Vincent’s; 100 MBq fixed-dose,
Netherlands Cancer Institute; 1.5 MBq/kg, Erasmus Medical
Centre). Imaging commenced at 60 min (St Vincents and
Erasmus Medical Centre) or 45 min (Netherlands Cancer
Institute) after injection. The scanning parameters at St
Vincents were: Philips Ingenuity TOF-PET/64-slice CT, i.v.
contrast-enhanced, dose-modulated CT scan with diagnostic
CT of abdomen/pelvis region and low dose CT for the
remaining whole body; whole-body PET acquisition 3 min/
bed position, with correction for randoms, scatter and decay
using the Philips Body-dynamic.xml and Body.xml
reconstruction protocol. The scanning parameters at the
Netherlands Cancer Institute were: Philips Gemini TF-II
PET/16-slice CT, dose-modulated low-dose CT scan (40 mAs,
2 mm reconstruction) from the proximal femora to skull
base, used for attenuation correction and anatomical
correlation, followed by PET imaging of the same region,
3 min per bed position for pelvis/abdomen and 2 min per
bed position for the remainder. The scanning parameters at
the Erasmus Medical Centre were: Siemens Biograph mCT,
dose-modulated low-dose CT scan (30 ref mAs, 3-mm
reconstruction) from proximal femora to skull base used for
attenuation correction and anatomical correlation, followed
by PET imaging of the same region with 3 min per bed
position for patients ≤70 kg and 4 min for patients >70 kg.
Imaging Analysis
All 68Ga-PSMA PET/CT scans were interpreted by
experienced nuclear medicine physicians. Positive sides were
divided into two main groups: inside the pelvic area (below
L4) or outside the pelvic area (above L5). Inside the pelvic
area was divided into the prostatic fossa, the pelvic lymph
nodes, or both. Outside the pelvic area was divided into
nodes, bones, or nodes and bones. If PCa recurrence was
detected both inside and outside the pelvic area, patients were
categorized as having recurrence outside the pelvic area. In
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addition, for all patients with a pelvic lymph node recurrence
at 68Ga-PSMA PET/CT, the anatomical region(s) of
recurrence (right or left external iliac, obturator fossa, internal
iliac or presacral space) was correlated to the anatomical
region(s) of the pathological positive node(s) in the ePLND at
time of RP.
Management Impact
Two experienced oncological urologists and two experienced
radiation oncologists determined proper standard therapies
based on patients’ characteristics and the 68Ga-PSMA PET/
CT results. ’Minor management impact’ was defined as
detection of PCa recurrence in the standard radiation field,
allowing for administation of extra high dosed radiotherapie
on visual lesions. ’Major management impact’ was defined as
detection of PCa recurrence outside the standard radiation
field, therefore averting any salvage radiotherapy to the pelvis.
Statistical Analysis
Means, median and frequencies were used as descriptive
statistics. We used descriptive statistics to report patient
population characteristics and detection rates of 68Ga-PSMA
PET/CT according to subsequent PSA group. A logistic
regression analysis was used to identify predictors for
pathological uptake outside the pelvic area, considering pT
stage, lymph node ratio, surgical margin status, grade group,
the time interval between RP and BCR, PSA persistence or BCR
after RP, and PSA level at the time of 68Ga-PSMA PET/CT.
PSA persistence after RP was defined as PSA >0.1 ng/mL
within 4 months after surgery. Subsequently, the probability of
finding distant metastases at PSMA PET/CT was statistically
analysed using univariate logistic regression, to assess the
correlation with the previously mentioned variables. In
addition, multivariable logistic regression analyses were used. P
values <0.05 were considered significant. Statistical analysis was
performed with SPSS v. 22 (IBM, Armonk, NY, USA).
Results
68Ga-PSMA PET/CT Results
A total of 100 patients were included in this retrospective
analysis. Patient characteristics are presented in Table 1. Of
the 100 patients included, 68 (68%) had a tumour-positive
68Ga-PSMA PET/CT at a median (interquartile range) PSA of
0.69 (0.42–1.26) ng/mL, 32 patients (32%) had a negative
68Ga-PSMA PET/CT scan at a median (interquartile range)
PSA of 0.26 (0.20–0.38) ng/mL (P < 0.05). The corresponding
percentages of positive 68Ga-PSMA PET/CT scans, stratified
by PSA level, are shown in Fig. 1.
Table 1 Patient characteristics.
All patients
(n = 100)
Patients with
positive 68Ga-PSMA
PET/CT (n = 68)
Patients with
negative 68Ga-PSMA
PET/CT (n = 32)
Age during 68Ga-PSMA PET/CT, years
Mean (SD) 67 (6.6) 67 (6.6) 66 (6.5)
Age at RP
Mean (SD) 65 (6.9) 65 (6.4) 64 (7.9)
PSA during 68Ga-PSMA PET/CT, ng/mL
Median (IQR) 0.49 (0.29–1.09) 0.69 (0.42–1.26) 0.26 (0.20–0.38)
Time interval RP – 68Ga-PSMA PET/CT
Months, median (IQR) 10 (4.9–28) 10 (5.1–33) 9.6 (4.5–19)
Tumour stage RALP, n (%)
≤pT2c 13 (13) 10 (15) 3 (9)
pT3a 27 (27) 20 (29) 7 (22)
pT3b 59 (59) 37 (55) 22 (69)
pT4 1 (1) 1 (1) 0 (0)
Positive margins, n (%) 29 (29) 20 (29) 9 (28)
ISUP grade, n (%)
2 21 (21) 9 (13) 12 (38)
3 27 (27) 15 (22) 12 (38)
4 18 (18) 16 (24) 2 (6)
5 28 (28) 22 (32) 6 (18)
Missing 6 (6) 6 (9) 0 (0)
Number of LNs removed at ePLND, median (IQR) 16 (12–22) 17 (13–19) 15 (12–19)
Number of positive LNs at ePLND, median (IQR) 1 (1–2) 1 (1–2) 1 (1–2)
PSA nadir (RP)
<0.1 ng/mL 38 (38) 25 (37) 13 (41)
≥0.1 ng/mL 47 (47) 32 (48) 15 (47)
Missing 15 (15) 11 (16) 4 (13)
68Ga-PSMA, gallium-68-prostate-specific membrane antigen; ePLND, extended pelvic lymph node dissection; IQR, interquartile range; ISUP, International Society of Urological
Pathology; LN, lymph node; PET, positron-emission tomography; RALP, robot-assisted laparoscopic prostatectomy; RP, radical prostatectomy.
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Anatomical Distribution of Pathological Lesions
Of the 68 patients with a positive 68Ga-PSMA PET/CT, 44
(65%) showed abnormal uptake only in the pelvic area, seven
(10%) only outside the pelvic area, and 17 (25%) both within
and outside the pelvic area (Fig. 2). Of the 44 patients with
68Ga-PSMA PET/CT uptake in the pelvic area, eight (18%),
29 (66%) and seven (16%) showed uptake in the fossa only,
in the pelvic lymph nodes only and in both the prostatic
fossa and the pelvic lymph nodes, respectively. Of the 24
patients with pathological uptake outside the pelvic area, 13
(54%), eight (33%) and three (13%) showed uptake in the
distant lymph nodes only, bones only and in both the lymph
nodes and bones, respectively (Fig. 3). In 36 patients, 68Ga-
PSMA PET/CT showed PCa recurrence in the pelvic lymph
nodes without evidence of distant metastases. In 31 of these
patients (86%), the exact anatomical location of the lymph
node metastasis at ePLND was known. In these patients, the
median number of removed lymph nodes during ePLND at
time of RP was 17. 68Ga-PSMA PET/CT detected lymph node
metastasis in the same anatomical location as the initial
lymph node metastasis in 10 patients (32%; eight out of 10 in
the obturator fossa). In 16 patients (52%), the lymph node
metastasis was detected in an adjacent anatomical region on
the same side of the pelvis (eight out of 16 in the presacral
space). In five patients (16%), the lymph node metastasis was
detected in an anatomical region on the contralateral side to
the initial lymph node metastasis.
Analysis of Risk Factors for Distant Metastases
Only PSA at the time of 68Ga-PSMA PET/CT was
significantly associated with the detection of PCa recurrence
outside the pelvic area (odds ratio 1.9, 95% CI 1.0–3.4;
P = 0.039 [Table 2]). The corresponding percentages of PCa
recurrences outside the pelvic area was 24% for PSA 0.0–
0.49 ng/mL, 28% for PSA 0.5–0.99 ng/mL, 43% for PSA
1.00–2.49 ng/mL, and 56% for PSA 2.5–5.0 ng/mL.
Management Impact
In 24 patients (24%), 68Ga-PSMA PET/CT detected PCa
recurrence outside the pelvic area, thus having a major
management impact. The detection of recurrence in the
pelvic lymph nodes or prostatic fossa in 44 patients (44%)
resulted in an adjusted radiotherapy plan with a boost to the
visible lesion (minor management impact).
Discussion
Today, there are conflicting opinions on the optimal
treatment strategy for patients with pathologically proven
lymph node metastases in their ePLND template at RP. Our
results show that two-thirds of these patients have their first
detectable early recurrence on 68Ga-PSMA PET/CT in the
prostatic fossa and/or pelvic lymph nodes. Pelvic lymph node
metastases identified by 68Ga-PSMA PET/CT were most often
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detected on the same side of the lymph node metastasis at
ePLND. On the one hand, by detecting PCa recurrence
outside the standard radiotherapy field, 68Ga-PSMA might
have avoided unsuccessful salvage therapy in one-third of the
patients considered for adjuvant or early salvage radiotherapy
to the pelvis. On the other hand, since most of the first
detectable PCa recurrences were located inside the pelvis,
adjuvant or early salvage radiotherapy might be the advocated
treatment strategy in these patients with high-risk PCa.
This is the first analysis to show the anatomical distribution
of PCa recurrence on 68Ga-PSMA PET/CT in patients with
BCR after RP with pN1 in the ePLND. The results show that
68Ga-PSMA PET/CT enables the identification of disease
All patients 
n = 100 
n = 32 
Positive PSMA scan 
n = 68 
Inside the pelvis 
n = 44 
Fossa 
n = 8 
Lymph nodes 
n = 29 
Fossa & lymph nodes 
n = 7 
Outside the pelvis
n = 24 
Lymph nodes 
n = 13 
Bone 
n = 8 
Lymph nodes & bone 
n = 3 
Negative 68Ga-PSMA scan 
Fig. 2 Overview of the anatomical distribution of recurrent prostate cancer in patients experiencing a biochemical recurrence after radical
prostatectomy with pathological node-positive extended lymph node dissection on gallium-68 prostate-specific membrane antigen (68Ga-PSMA)
positron-emission tomography (PET)/CT.
A
B
C
D
E
F
Fig. 3 Example showing a patient with PSA 1.46 ng/mL and positive lesions in and outside the pelvis area. Non-contrast-enhanced CT images (A, C
and E) with corresponding fused gallium-68 prostate-specific membrane antigen (68Ga-PSMA) positron-emission tomography/CT images (B, D and F).
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recurrence in most of these patients. However, there remains
a lack of evidence from prospective studies to support the
long-term benefit of 68Ga-PSMA PET/CT-dictated
management changes. A previous study showed a 0%
detection rate for lymph node metastases <2 mm using 68Ga-
PSMA PET/CT, a 60% detection rate for lesions 2.0–4.9 mm
and an 86% detection rate for lymph node metastases
≥5.0 mm [11]. Thus, currently 68Ga-PSMA PET/CT
underestimates the extent of the disease, and patients with
lymph node-positive PCa often harbour microscopic
metastatic PCa. Our detection rates, stratified by the different
PSA values, are in accordance with earlier publications [12].
In our analysis, we did not focus on other predictors of
positive 68Ga-PSMA PET/CT, such as grade group, and the
study only included patients with high-risk PCa, and the
correlation between predictors and the chance of having a
positive PSMA PET/CT has already been described and
externally validated [12].
In their retrospective analysis of 209 patients with pN1 ePLND
at RP, Mandel et al. [13] showed that, of the patients with a
limited nodal disease (one to two positive lymph nodes), 37%
remained metastasis-free at a median follow-up of 60.2 months
without the need for salvage treatment. Seiler et al. [14] showed
that a subset (8%) of the 88 patients who had undergone RP
and had tumour-positive ePLND without adjuvant treatment
had not experienced BCR at a median follow-up of 15 years. In
a systematic review of oncological outcomes after salvage
lymph node dissection, Ploussard et al. [15] reported 2- and 5-
year BCR-free survival of 23–64% and 6–31%, respectively, in
patients with a tumour-positive salvage ePLND. These results
support early localization of loco-regional disease recurrence in
order to benefit from salvage therapies.
Pelvic lymph node metastases identified by 68Ga-PSMA PET/
CT were detected on the same side as the node metastasis at
ePLND in 84% of the cases, and in the same anatomical
region as the initially diagnosed lymph node metastasis in
32% of the cases. This suggests an incomplete ePLND.
Briganti et al. [16] have shown that the estimated number of
lymph nodes necessary for optimal staging accuracy ranges
between 20 and 28. Abdollah et al. [17] reported that the
removal of 20 nodes resulted in accurate staging in 90% of
their patients. Of the 31 patients with PCa recurrence
detected on 68Ga-PSMA PET/CT in the pelvic lymph nodes
only, ≥20 lymph nodes were removed during ePLND in only
11 patients (35%), suggesting a suboptimal ePLND in most of
the patients. This may explain the high probability of pelvic
lymph node recurrence on the same side as the initial lymph
node metastasis, and suggests a role for adjuvant therapy (e.g.
radiotherapy) at least in lymph node-positive patients at RP
with a limited number of nodes removed at ePLND.
Abdollah et al. [18] showed that, in patients with PCa with
lymph node metastases, the removal of a higher number of
lymph nodes during RP was associated with improvement in
the cancer-specific survival rate. Also, they identified the
optimal candidates for adjuvant radiotherapy among patients
with lymph node-positive PCa at RP, i.e. those with one to two
positive nodes, pathological Gleason score 7–10 and pT3b/4
disease, and those with three to four positive nodes, regardless
of local characteristics [19]. In the present study, two-thirds of
the patients had their first detectable recurrence at 68Ga-PSMA
PET/CT in the prostatic fossa and/or pelvic nodes. In other
words, a subset of these patients might have been ideal
candidates for adjuvant radiotherapy, with potentially
improved outcomes. This finding suggests adjuvant
radiotherapy of the pelvis in a selection of patients with lymph
node positive PCa at RP should at least be considered.
Only PSA level at time of the scan was a significant predictor
for the detection of metastatic disease outside the pelvic area
on 68Ga-PSMA PET/CT. Patients with biochemical
persistence after RP have worse prognosis and higher risk of
a positive 68Ga-PSMA PET/CT than patients with an
undetectable PSA after RP, regardless of the pN1 status [20].
In the present univariable and multivariable analyses, a higher
rate of detection of metastatic disease outside the pelvic area
was not observed in patients with biochemical persistence
compared to patients with BCR; therefore, patients with PSA
persistence should not automatically be excluded from salvage
radiotherapy to the prostatic fossa and pelvic lymph nodes.
However, our multivariable analysis was limited in its
Table 2 Regression analysis of the probability of finding distant
metastases.
Clinical variable Univariable
analysis
Multivariable
analysis
OR (95% CI) P OR (95% CI) P
ISUP grading
GG2 Reference -
GG3 1.0 (0.3–3.5) 0.9 1.0 (0.2–5.2) 0.8
GG4 0.6 (0.1–2.9) 0.5 0.4 (0.05–3.7) 0.6
GG5 0.8 (0.2–2.8) 0.7 0.3 (0.03–1.9) 0.3
LNR 5.6 (0.02–1522.8) 0.5 0.2 (0.0–365.0) 0.6
Surgical margin RP
No Reference –
Yes 0.9 (0.4–2.4) 0.9 2.0 (0.5–7.8) 0.3
PSA at 68Ga-PSMA
PET/CT
1.6 (1.0–2.3) 0.034 1.9 (1.0–3.4) 0.039
Time RP and
68Ga-PSMA
1.0 (1.0–1.0) 0.8 0.9 (0.8–1.0) 0.081
T-stage
pT2 Reference –
pT3a 0.6 (0.1–2.9) 0.6 1.0 (0.1–7.5) 0.9
pT3b 0.5 (0.1–1.8) 0.3 1.0 (0.2–6.6) 0.9
BCR persistence
BCR Reference –
Persistence 1.5 (0.5–4.4) 0.4 0.5 (0.1–2.6) 0.4
68Ga-PSMA, gallium-68-prostate-specific membrane antigen; BCR, biochemical
recurrence; GG, grade group; ISUP, International Society of Urological Pathology;
LNR, lymph node ratio; OR, odds ratio; RP, radical prostatectomy.
6
© 2020 The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International
Huits et al.
statistical power, and larger cohorts of patients are required
in order to evaluate the true correlation.
Based on current guidelines, the available management
recommendations are limited by the level of evidence for the
treatment of men with tumour-positive ePLND at time of the
RP. Treatment options are to start either ADT, adjuvant ADT
combined with radiotherapy, or observation. Observation
with possible (early) salvage radiotherapy combined with
ADT in case of BCR is not listed in these guidelines. 68Ga-
PSMA PET/CT has been reported to have a management
impact in roughly two out of three individuals with BCR after
RP [21]. In our selection of pN1 patients, in one-third of
these patients the primary location of disease recurrence on
68Ga-PSMA PET/CT was outside the pelvic area; therefore,
adjuvant radiotherapy to the prostatic fossa and pelvis would
likely result in missing the correct location of the recurrence
and subsequent treatment failure in these patients. As a
consequence, the results suggest a role for 68Ga-PSMA PET/
CT-guided salvage therapy in patients with pN1 ePLND,
enabling better patient selection. Also, 68Ga-PSMA PET/
CT might be used for detection and treatment planning by
fusing the 68Ga-PSMA with the planned CT to allow ’dose
sculpting’, that is, delivering a high dose to macroscopic
disease while better sparing the surrounding normal tissue. In
our cohort, 68Ga-PSMA PET/CT would have allowed dose
sculpting in 44 of the 100 patients. This results in a more
personalized approach, which may also decrease
radiotherapy-related toxicity.
The present study has several limitations. First, it was a
retrospective analysis of a relatively small sample size and
therefore has relatively low statistical power. Nevertheless, the
aim of the study was to generate a hypothesis, rather than
define recommendations in this patient population. Second,
68Ga-PSMA PET/CT was not performed at a predefined
serum PSA level and the different institutions had different
imaging protocols; therefore, some patients did not have
multiple PSA values available before 68Ga-PSMA PET/CT and
calculation of PSA doubling time was not possible. Third, all
patients underwent MRI/CT and bone scintigraphy for
primary staging. 68Ga-PSMA PET/CT is often used for
preoperative staging. This might influence location of
recurrence in these patients. Fourth, different imaging
analysis methods were used among the different centres;
however, all nuclear physicians were experienced in reporting
68Ga-PSMA PET/CT. These results, therefore, might not be
directly applicable to clinical practice. Lastly, no follow-up
data are yet available and consequently, it is unknown to
what extent 68Ga-PSMA PET/CT has missed disease
recurrences outside the pelvis. Nevertheless, to date, this is
the first and largest study on this subject in a population that
underwent RP with a pN1 ePLND. Future studies should
focus on the efficacy of 68Ga-PSMA-guided salvage therapies.
In conclusion, patients with BCR after RP with pN1 ePLND
are a heterogenous population; therefore, having a clear vision
of disease spread in such patients is essential. In this study,
most of the first 68Ga-PSMA PET/CT-detectable disease
recurrence was located inside the pelvis, with positive pelvic
lymph nodes often detected on the same side as the lymph
node metastasis at ePLND. This study confirms the value of
68Ga-PSMA PET/CT for the detection of PCa recurrence at
low PSA values in men with BCR after RP, and highlights the
importance of high-quality ePLND. Finally, prospective
studies are needed to support the long-term benefit of 68Ga-
PSMA PET/CT-dictated management changes.
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